Here's Why Dermira Stock Popped Today

Shares of Dermira (NASDAQ: DERM), a biopharmaceutical company, jumped at the beginning of today's trading session in response to good news from the Food and Drug Administration. Investors looking forward to a shortened review for the company's experimental eczema therapy drove the stock 9.8% higher as of 12:10 p.m. EST on Tuesday.

Impressive results from a midstage clinical trial persuaded the FDA to give Dermira's eczema candidate lebrikizumab a fast-track designation. Benefits that come with the designation include increased access with regulators before filing a new drug application and a shortened six-month review instead of the standard 10 months.

Image source: Getty Images.

Source Fool.com